Target Name: RBBP6
NCBI ID: G5930
Review Report on RBBP6 Target / Biomarker Content of Review Report on RBBP6 Target / Biomarker
RBBP6
Other Name(s): RB binding protein 6, ubiquitin ligase, transcript variant 1 | PACT | E3 ubiquitin-protein ligase RBBP6 (isoform 2) | proliferation potential-related protein | P2P-R | E3 ubiquitin-protein ligase RBBP6 | E3 ubiquitin-protein ligase RBBP6 (isoform 1) | Retinoblastoma binding protein 6 | MY038 | RB binding protein 6, ubiquitin ligase | Proliferation potential-related protein | Retinoblastoma-binding protein 6, isoform 3 | RBBP6 variant 2 | retinoblastoma binding protein 6 | RBBP6_HUMAN | SNAMA | RBBP6 variant 1 | protein P2P-R | Retinoblastoma-binding protein 6 | Protein P2P-R | retinoblastoma-binding Q protein 1 | PP-RP | RB binding protein 6, ubiquitin ligase, transcript variant 2 | RB-binding Q-protein 1 | RBQ-1 | p53-associated cellular protein of testis | RING-type E3 ubiquitin transferase RBBP6 | Retinoblastoma-binding Q protein 1

Unveiling the Potential of RBBP6 as a Drug Target and Biomarker

Introduction

RBBP6, or Ubiquitin Ligase 6, is a protein that plays a crucial role in the regulation of protein stability and dynamics in the cell. It is a member of the ubiquitin gene family, which is known for its role in protein degradation and modification. RBBP6 has been identified as a potential drug target and biomarker due to its unique structure, function, and expression patterns.

Structure and Function

RBBP6 is a 23-kDa protein that consists of 218 amino acid residues. It has a unique 11-amino acid residue at its N-terminus, which is involved in its stability and functions as a binding site for other proteins. RBBP6 also has a 254-amino acid longitudinal region that is involved in its catalytic activity.

RBBP6 functions as a ubiquitin ligase, which means it catalyzes the covalent attachment of the ubiquitin molecule to target proteins. This process is critical for protein stability and dynamics, as well as cell signaling pathways. RBBP6 uses its 11-amino acid residue at the N -terminus to interact with other proteins and its 254-amino acid longitudinal region to catalyze the attachment of ubiquitin.

RBBP6 has been shown to play a critical role in the regulation of various cellular processes, including cell signaling, DNA damage repair, and metabolism. It has been shown to interact with numerous proteins, including histone modifications, non-histone modifications, and protein- protein interactions.

Gene Expression and Expression

RBBP6 is highly expressed in various tissues and cell types, including the brain, muscle, liver, and pancreas. It is also expressed in various cell lines, including cancer cells. The expression level of RBBP6 is affected by a variety of regulatory factors, including post-transcriptional Modification, DNA binding proteins, protein binding, etc.

Expression of RBBP6 has been shown to be associated with various cellular processes, including cell proliferation, apoptosis, and autophagy. It has also been shown to be involved in the regulation of cellular signaling pathways, including cell cycle, mitosis, apoptosis, and autophagy. Metabolism etc.

Drug Targeting

RBBP6 has been identified as a potential drug target due to its unique structure and function. The 11-amino acid residue at its N-terminus makes it a potential target for small molecules or antibodies that can modulate its stability or activity. The 254-amino Acid longitudinal region also provides a potential target for drugs that can alter its catalytic activity.

Preclinical studies have shown that RBBP6 can be effectively targeted with small molecules, such as inhibitors of tyrosine phosphorylation or inhibitors of its activity as a ubiquitin ligase. These small molecules have been shown to reduce the levels of RBBP6 in various cell types, including cancer cells , and to inhibit its activity in cell signaling pathways.

Biomarker

RBBP6 has also been identified as a potential biomarker for various diseases, including cancer. Its expression has been shown to be elevated in various types of cancer, including breast, lung, and colorectal cancer. This increased expression has been associated with poor prognosis and increased disease severity.

In addition, RBBP6 has also been shown to be involved in the regulation of cellular processes that are sensitive to disease, such as apoptosis, autophagy, and metabolism. This suggests that changes in RBBP6 expression levels may be a potential diagnostic or therapeutic target for diseases that affect these processes, such as cancer.

Conclusion

RBBP6 is a unique protein that plays a critical role in the regulation of protein stability and dynamics in the cell. Its 11-amino acid residue at the N-terminus makes it a potential target for small molecules or antibodies that can modulate its stability or activity . The 254-amino acid longitudinal region also provides a potential target for drugs that can alter its catalytic activity.

In addition, RBBP6 has

Protein Name: RB Binding Protein 6, Ubiquitin Ligase

Functions: E3 ubiquitin-protein ligase which promotes ubiquitination of YBX1, leading to its degradation by the proteasome (PubMed:18851979). May play a role as a scaffold protein to promote the assembly of the p53/TP53-MDM2 complex, resulting in increase of MDM2-mediated ubiquitination and degradation of p53/TP53; may function as negative regulator of p53/TP53, leading to both apoptosis and cell growth (By similarity). Regulates DNA-replication and the stability of chromosomal common fragile sites (CFSs) in a ZBTB38- and MCM10-dependent manner. Controls ZBTB38 protein stability and abundance via ubiquitination and proteasomal degradation, and ZBTB38 in turn negatively regulates the expression of MCM10 which plays an important role in DNA-replication (PubMed:24726359)

The "RBBP6 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RBBP6 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

RBBP7 | RBBP8 | RBBP8NL | RBBP9 | RBCK1 | RBFA | RBFOX1 | RBFOX2 | RBFOX3 | RBIS | RBKS | RBL1 | RBL2 | RBM10 | RBM11 | RBM12 | RBM12B | RBM14 | RBM14-RBM4 | RBM15 | RBM15-AS1 | RBM15B | RBM17 | RBM17P1 | RBM18 | RBM19 | RBM20 | RBM22 | RBM22P1 | RBM23 | RBM24 | RBM25 | RBM26 | RBM26-AS1 | RBM27 | RBM28 | RBM3 | RBM33 | RBM34 | RBM38 | RBM39 | RBM4 | RBM41 | RBM42 | RBM43 | RBM43P1 | RBM44 | RBM45 | RBM46 | RBM47 | RBM48 | RBM48P1 | RBM4B | RBM5 | RBM5-AS1 | RBM6 | RBM7 | RBM8A | RBMS1 | RBMS1P1 | RBMS2 | RBMS2P1 | RBMS3 | RBMS3-AS3 | RBMX | RBMX2 | RBMX2P1 | RBMXL1 | RBMXL2 | RBMXL3 | RBMY1A1 | RBMY1B | RBMY1D | RBMY1F | RBMY1J | RBMY2EP | RBMY2FP | RBP1 | RBP2 | RBP3 | RBP4 | RBP5 | RBP7 | RBPJ | RBPJL | RBPJP2 | RBPMS | RBPMS-AS1 | RBPMS2 | RBSN | RBX1 | RC3H1 | RC3H2 | RCAN1 | RCAN2 | RCAN3 | RCAN3AS | RCBTB1 | RCBTB2 | RCC1